This is a preview of subscription content, log in via an institution to check access.
Reference
Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective ClinicoEconomics and Outcomes Research : 22 Oct 2021. Available from: URL: https://doi.org/10.2147/CEOR.S328433
Rights and permissions
About this article
Cite this article
Dapagliflozin cost effective vs sulfonylureas as second-line therapy for T2DM in India. PharmacoEcon Outcomes News 891, 8 (2021). https://doi.org/10.1007/s40274-021-08166-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08166-9